Oncology
FDA grants ODD to Candel Therapeutics’ pancreatic cancer treatment
April 15, 2024Medical Communications Candel Therapeutics, FDA, ODD, Oncology, Pancreatic cancer
Candel Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CAN-2409, …
TILT Biotherapeutics shares data on TILT-123 with Keytruda for ovarian cancer treatment
April 10, 2024Research and Development Merck, National Cancer Institute, Oncology, TILT Biotherapeutics, keytruda, ovarian cancer
TILT Biotherapeutics has announced promising preliminary safety and efficacy data from its ongoing phase 1 clinical trial (NCT05271318) in platinum …
FDA clears Oryzon’s phase 1/2 trial for lung cancer treatment
April 10, 2024Research and Development FDA, Oncology, Oryzon, lung cancer
Oryzon Genomics has announced that the US Food and Drug Administration (FDA) has approved its investigational new drug (IND) application …
Geneos Therapeutics shares data from phase 1/2 trial for cancer vaccine
April 8, 2024Research and Development Cancer, Geneos Therapeutics, Oncology, clinical trial
Geneos Therapeutics has announced that it has published positive safety, immunogenicity and efficacy data from the full cohort of patients …
AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer
April 5, 2024Research and Development AstraZeneca, Imfinzi, Oncology, clinical trial, lung cancer
AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that Imfinzi (durvalumab) had a statistically …
FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment
April 2, 2024Research and Development AstraZeneca, Daiichi Sankyo, FDA, Oncology, bla, breast cancer
AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan (Dato-Dxd) has been accepted in …
Heidelberg Pharma gains FDA ODD for ATAC candidate
March 27, 2024Research and Development FDA, Oncology, heidelberg pharma, multiple myeloma
Heidelberg Pharma has announced that it has gained Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) …
Curve Therapeutics’ CSO publishes research on HIF inhibition for cancer treatment
March 26, 2024Research and Development Cancer, Curve Therapeutics, HIF inhibition, Oncology, oncology
Curve Therapeutics has announced that its chief scientific officer, Professor Ali Tavassoli has published research in the Journal of the …
AstraZeneca to acquire Fusion for approximately $2bn
March 19, 2024Business Services AstraZeneca, Fusion Pharmaceuticals, Oncology, acquisition, radioconjugates
AstraZeneca has announced that it has entered into a definitive agreement to acquire Fusion Pharmaceuticals for an approximate $2bn. This …
GSK shares data from phase 3 trial for Jemperli combinations for endometrial cancer treatment
March 18, 2024Research and Development GSK, Jemperli, Oncology, clinical trial, endometrial cancer, women's health
GSK has announced positive results from part 1 and part 2 of its RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial for Jemperli (dostarlimab) …
Merck shares results for Keytruda in cervical cancer treatment
March 18, 2024Research and Development Merck, Oncology, cervical cancer, keytruda, women's health
Merck, known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-A18 trial, …
Bayer and Aignostics to collaborate for AI oncology research
March 14, 2024Research and Development AI, Bayer, Oncology, research
Bayer and Aignostics have announced that they have entered into a strategic collaboration for several artificial intelligence (AI)-powered approaches for …
Merck completes acquisition of Harpoon Therapeutics for $650m
March 12, 2024Business Services Harpoon Therapeutics, Merck, Oncology, lung cancer
Merck, known as MSD outside of the US and Canada, has announced that it has completed the acquisition of Harpoon …
Johnson & Johnson acquires Ambrx Biopharma for approximately $2bn
March 11, 2024Business Services ADCs, Ambrx Biopharma, J&J, Johnson & Johnson, Oncology, acquisition
Johnson & Johnson (J&J) has announced that it has successfully completed its acquisition of Ambrx Biopharma in an all-cash merger …
BeiGene’s Brukinsa gains FDA accelerated approval for follicular lymphoma treatment
March 8, 2024Medical Communications BeiGene, Brukinsa, FDA, Oncology, follicular lymphoma
BeiGene has announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Brukinsa (zanubrutinib) for the …
Latest content
FibroFind appoints Lee Borthwick as CEO
